Ventrus Biosciences Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin in Patients With Hemorrhoidal Disease
Ventrus Biosciences, Inc. (Nasdaq: VTUS) announced that it has completed patient enrollment and randomization in the first Phase 3 clinical trial of iferanserin (VEN 309) in patients with grade 1-3 hemorrhoids. Data from the Phase 3 study are anticipated to be available in late June or early July 2012.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.